Navigation Links
Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel,Anticancer Agents, at AACR

s of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for multiple myeloma in combination with Velcade(R) (bortezomib) and HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). In addition, intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement.

For additional information on Kosan Biosciences, please visit the company's website at www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements relating to the further development and potential safety, efficacy and commercialization of Kosan's product candidates; and initiations of pre-clinical and clinical studies and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of Kosan t
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference

Post Your Comments:
(Date:11/25/2009)...ESTON,Fla., Nov.25/PRNewswire-FirstCall/--America...any")ispleasedtoannouncethattheyhaveopenedaregiona...China. ,, ASRhasbeenabletosecurealocationabroad...oductionofcurrentandfuturehealthandsafetyproductsf...CurrentlythecompanyhousesinventoryinthestateofOhio...
(Date:11/25/2009)...HICAGOandSTAFA,Switzerland,Nov.25/PRNewswire/-- Fr...ovativehearingsolutions,presentedthesecondeditiono...ecialneedsoftheolderpopulation.Theconferencebrough...ndtheworldandmorethan250clinicianswhoworkeverydayw...reexperiencesanddiscussthelatestresearchandtrendsi...
(Date:11/25/2009)...ANCHOCORDOVA,Calif.,Nov.25/PRNewswire/--AMPACFineC...ration(Nasdaq: APFC )announcedtodaythatitreceivedt...dattheAnnualStatewideEnvironmentalSummit,sponsored...on(CMTA),theIndustrialEnvironmentalAssociation(IEA...ldinSanDiego.Thisisthemostprestigiousawardavailabl...
Breaking Medicine Technology:American Scientific Resources Inc. Opens Shanghai Location 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2Spallation Neutron Source first of its kind to reach megawatt power 10168 1Spallation Neutron Source first of its kind to reach megawatt power 10168 2Could the Recession Be Good for Your Health 3F 58477 1Could the Recession Be Good for Your Health 3F 58477 2Could the Recession Be Good for Your Health 3F 58477 3Could the Recession Be Good for Your Health 3F 58477 4Revolutionary statewide UC collaboration targets breast cancer 58472 1Revolutionary statewide UC collaboration targets breast cancer 58472 2Revolutionary statewide UC collaboration targets breast cancer 58472 3Revolutionary statewide UC collaboration targets breast cancer 58472 4Revolutionary statewide UC collaboration targets breast cancer 58472 5
... ARNHEM, The Netherlands, April 16 The European...deration the recent,scientific information on rand...¶der et al, NEJM 2009). Based on the results of th...ate Cancer (ERSPC), the EAU has formulated a,posit...in Europe, and the,subsequent actions to be taken ...
...nly 39 Percent of Newly Diagnosed Patients Receive...According to a New Report from Decision Resources ...Decision Resources, one of the world,s leading res...l and healthcare issues, finds that surveyed neuro...eir use of emerging oral agents --- Merck Serono,s...
Other Medicine Technology:EAU Position Statement on Screening for Prostate Cancer 2Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line 2Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line 3
(Date:11/27/2009)... Voyant Health™ announced today t...icensed its TraumaCad Enterprise orthopedic templa...lution. , (PRWEB) Novembe... that Spectrum Health (Grand Rapids, Michigan) has...lating solution and its TraumaCad Extend workflow ...
(Date:11/27/2009)... Three new interactive anatomy educatio... Wilkins expand health sciences learning opportuni... Durham, NC (Vocus) November 27, 2009 -- M...ns (LWW), a division of Wolters Kluwer Health, tod... education apps on the App Store. Clemente’s...
(Date:11/26/2009)...25 years, the number of Americans living with diab...ion in 2009 to 44.1 million in 2034. Over the same...rising from $113 billion to $336 billion, even wit...chers based at the University of Chicago report in...mber of those with diabetes covered by Medicare wi...
(Date:11/26/2009)...ger thrill when on an emotional rollercoaster, stu...y News) -- Call it the fear factor meets the jubil...ctators -- especially those who root for the winni... a closely contested match and victory was in doub..., Chew on that this Thanksgiving weekend as you,...
(Date:11/26/2009)... Research Triangle Dental (RTDental), a...rolina, today announced the expansion of its servi...entist, Dr. Doug Macmillan. , ...ntal is pleased to announce that Dr. Doug Macmilla...mpleted an additional advanced training seminar. ...
Breaking Medicine News(10 mins):Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2
... of male infertility is variococeles; blocked vari...f scientists attending the yearly meeting of// the...h a presentation of how this problem can be solved...ry may rectify this problem. The procedure terme...
...of Meningitis C last week. Public health departmen...is case //since the disease is highly contagious a...bustling bar days before he died. Although on...a contagious disease caused by bacteria present in...
...t has decreed all hospitals in Britain, to furnish...pend by cancer patients// at hospitals in Britain....r. It will help cancer survivors to choose whi...a conference in London. This conference was conduc...
...urnal of Bone and Mineral Research study by Indian...) researchers, exercise when young may reduce risk...ailable in an advance online edition of the journa...d the old exercise adage of 'use it or lose it' ma...
...oms among the gay population will be promoted sign...project is scheduled to be flagged off in the comi...in number of HIV infections across the nation. ... time of sexual contact. At present, surveys have ...
...s groups suggests that Pregnant women and those tr...pressants like Paxil due to the risk of birth defe...ge of Obstetricians and was published as an opinio...go, which showed the drug poses risk to the fetus ...
Other Medicine News:Health News:Exercise In Childhood Provides Lifelong Benefits 2
Nerve Hook - Right
Single Skin Hook
Smith Expressor Hook
Osher "Y" Hook
Medicine Products: